Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma

Keyphrases

• Tumor Immunity 100%
• Heat Shock Proteins 100%
• Cytotoxic T Lymphocytes 100%
• Multiple Myeloma 100%
• Myeloma Cells 41%
• Myeloma 33%
• Protein-peptide Complexes 33%
• HLA-A*0201 33%
• Heat Shock Protein 90 (Hsp90) 16%
• HSPB1 16%
• Cancer Patients 8%
• Tumor Burden 8%
• Cancer Immunotherapy 8%
• Immune Response 8%
• Peripheral Blood Mononuclear Cells 8%
• Plasma Cells 8%
• Immunogenicity 8%
• Transgenic Mice 8%
• Tumor Cells 8%
• Dendritic Cells 8%
• MHC Class II 8%
• Tumor Antigen 8%
• Cell Survival 8%
• Healthy Volunteers 8%
• Heat Shock Protein 27 (HSP27) 8%
• Cell-derived 8%
• Binding Peptide 8%
• Xenograft Mouse Model 8%
• Established Cell Lines 8%
• Primary Plasma 8%

Immunology and Microbiology

• Heat Shock 100%
• Cytotoxic T Cell 100%
• Multiple Myeloma 100%
• Peptides 58%
• Myeloma Cell 41%
• Immunotherapy 16%
• Mouse Model 8%
• Peripheral Blood Mononuclear Cell 8%
• Immune Response 8%
• Immunoglobulin Producing Cell 8%
• Major Histocompatibility Complex 8%
• Immunogenicity 8%
• Dendritic Cell 8%
• Cell Line 8%
• Normal Human 8%
• Tumor Antigen 8%
• Cell Survival 8%
• Tumor Cell 8%
• Transgenic Mouse 8%
• Xenograft 8%
• Tumor Volume 8%
• In Vitro 8%